| Date | Title | | | | 05/16/13 | Clovis Oncology Announces Clinical Data to be Presented at ASCO Annual Meeting 2013| BOULDER, Colo.--(BUSINESS WIRE)--May. 16, 2013--
Clovis Oncology (NASDAQ:CLVS) announced that three abstracts (ASCO
Abstracts #2524, #2585, #2586) highlighting results from three Phase I
studies of the company’s two lead compounds will be presented at the
American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in
Chicago.
Data contained in the published abstracts was current as of the
submission deadline of February 5th, 2013. Dat... |
|  |  | | 05/08/13 | Clovis Oncology to Present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas| BOULDER, Colo.--(BUSINESS WIRE)--May. 8, 2013--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast,
the Company’s Chief Financial Officer and Executive Vice President, will
present at the Bank of America Merrill Lynch 2013 Health Care Conference
on Wednesday, May 15, 2013, at 10:40 AM PDT. The conference will be held
at the Encore at the Wynn in Las Vegas.
A live webcast of the presentation can be accessed through the investor... |
| | | | 05/07/13 | Clovis Oncology Announces First Quarter 2013 Operating Results| BOULDER, Colo.--(BUSINESS WIRE)--May. 7, 2013--
Clovis
Oncology, Inc. (NASDAQ:CLVS) today reported financial results for
its first quarter ended March 31, 2013, and provided an update for its clinical
development programs. This update describes, for the first time, the
Company’s progress in developing a new formulation for CO-1686,
including results from a recently initiated pharmacokinetic (PK) study
in healthy human volunteers.
“D... |
| | |
|
